• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Export to ExcelExport to Excel
General
Application Number P030031 S011
Most Recent Protocol Version Approved 11/24/2009
Study Name CABANA Trial
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Other Study Design
Study involve follow-up of premarket cohort (Y/N) No
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description The purpose of this study is to provide long term data on the incidence of   show the rest ...
Study Population Description Study Population: The proposed study is a subgroup analysis of data to be collected in   show the rest ...
Sample Size A total of 3000 patients will be randomized in a 1:1 fashion to a strategy   show the rest ...
Data Collection The primary endpoint for this subgroup analysis is the incidence of stroke. The sponsor will   show the rest ...
Followup Visits and Length of Followup Patients in the trial will be randomized, treated, and followed up for a median of   show the rest ...


CABANA Trial Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
18 month report 08/16/2010 08/16/2010 On Time
2 year report 02/06/2011 02/02/2011 On Time
3 year report 02/06/2012 02/02/2012 On Time
4 year report 02/05/2013 02/05/2013 On Time
5 year report 02/05/2014 02/05/2014 On Time
6 year report 02/05/2015    

Show All Studies

-
-